anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diffuse large B cell lymphoma (DLBCL), as the most common subtype non-Hodgkin lymphoma (NHL), accounts for 30％～40％ of adults with NHL, and has great heterogeneity in clinical manifestations, histological morphology and prognosis. R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone) is the gold therapeutic criteria for patients with NHL, and it is also used as the first-line treatment for patients with DLBCL. After treatment, 50％～60％of patients with DLBCL receive complete remission (CR), 30％～40％ recurrent and 10% will never be cured due to initial and secondary drug tolerance. The study of Tao Wu et al in domestic showed that cinobufacini combined with CHOP protocol had excellent efficacy in the treatment of NHL, with response rate reaching up to 91.7%, and the adverse reactions were mild and tolerable, whereas the response rate of single CHOP was only 62.5%. In the clinical practice of our studies, it was also found that some patients with recurrent DLBCL NHL also had shrunken or disappeared tumors and a survival time of more than 2 years after single administration of cinobufacini tablets for 3\~6 months following the withdrawal of chemotherapy. This study aimed to explore whether Cinobufacini Tablets had synergistic effect in the treatment of DLBCL, and whether its action was in close association with the positive expression of Na+/K+-ATPase α3, and to observe the rates of adverse reactions induced by Cinobufacini Tablets during treatment.
PURPOSE: To obtain an anti-mutagenicity enhancing food and enhancer having excellent safety by including chitosan heat-treated at a temperature higher than a prescribed temperature as an active component. CONSTITUTION: The aimed anti-mutagenicity enhancing food and enhancer individually includes chitosan heat-treated preferably at a temperature about 250 deg.C for a heating time of 10-35min. Said chitosan is preferably obtained by using shells of Crustacea such as crabs or prawns as a raw material, removing protein with heating in a dilute alkaline aqueous solution, washing, removing calcium component in a dilute acidic aqueous solution, simultaneously controlling molecular weight, washing to obtain chitin and deacetylating, etc. Heat-treated chitosan is added to food, etc., and ingested. Otherwise, the resultant chitosan is orally administrated directly as a powder agent. The heat-treated chitosan is thought to manifest the effect by adsorbing a mutagen and especially a strong anti-mutagenicity to a heterocyclic amine.
The invention relates to a liquid cleaning product for removable dental prostheses. The liquid cleaning product of the invention is an aqueous solution containing hydrochloric acid, hydrogen peroxide and at least one preservative, in which solution, per 1,000 ml, the volume of hydrochloric acid in relation to its content in % by weight is determined by the graph in Fig. 4, entailing the following values: 40 % by weight.............    18.12 ml       20 % by weight.............    36.23 ml       10 % by weight............. 72.46 ml        4.388 % by weight.........   165.13 ml        3.374 % by weight.........   214.76 ml.   The volume of hydrogen peroxide in relation to its content in % by weight and its value in degrees with respect to volume is determined by the graphs in Fig. 1, 2, 3, entailing the following values: 50 % by weight......    220 DEG  with respect to volume....10 ml 24.99% by weight....    110 DEG  with respect to volume....20 ml   9 % by weight......     40 DEG  with respect to volume....55 ml.   The liquid cleaning product of the invention enables impurities and tartar to be removed by immersion for a period not exceeding 8 h. <IMAGE>
A method for integrating and displaying medical data in which a computer program links a flow sheet of a medical record to medical charts. The flow sheet has a standardized time scale in the rows and a group of data items in the columns. The program determines the position of a cursor in the flow sheet, and interpolates or erases data in cells of the flowsheet as appropriate. Each empty data cell between cells containing real data is interpolated according to a predetermined formula. The interpolation method can be one in which an average of the preceding cell and the subsequent cell are recalculated up to several hundred times. Another interpolation method involves the use of a gradient, row values and an intercept. The resulting medical charts are designed so that therapeutic data and clinical data are simultaneously displayed on the same chart with the same time scale. The system can be connected to a client server system of a computer network. The system allows the comparison of regularly collected data of many patients because it has a standardized time scale and data interpolated by an appropriate formula.
This study, which was planned as a randomized controlled intervention study, was conducted to compare the effects of the Dietary Approaches to Stop Hypertension (DASH) and salt-free diet on blood pressure in patients with hypertension. The study was complited with the participation of 60 hypertensive individuals (46 females, 14 males) who applied to between July 2019 and March 2020. Patients with hypertension who were living in Kayseri province, at least elementary school graduate, in the 20-65 age group, able to communicate with the researcher face to face and by phone, diagnosed with hypertension at least 4 weeks ago, and whose medication did not change were included in the study. One group (n = 30) received the DASH diet and the other group received a salt-free diet (n = 30) and was followed for 2 months. Research data was repeated during application with the face-to-face interview method. Research data was collected through a questionnaire containing questions about the sociodemographic characteristics, nutritional habits, chronic diseases, and medications of the individuals. Anthropometric measurements of the patients were made and blood and urine samples were taken. Food consumption frequency was noted, DASH diet compliance scale and International Physical Activity Questionnaire (IPAQ) short form were applied.
PURPOSE: To provide an osteogenesis compsn. capable of forming a non- absorbable and long-lasting hard neobone in treatment of a bone fracture, skeletal defect, surgical restoration and maxillofacial reconstruction. CONSTITUTION: This osteogenesis compsn. includes the mineral disappearing bone substrate (DBM) opearbtively bonded to a tumor growth factor-β (TGF-β) and a pharmaceutically permissible carrier and is used for stimulating the generation of the bone in the vital region where the formation of the neobone is desired. The DBM is the bone deriv. prepd. by subjecting the bone to mineral disappearance with hydrochloric acid, then to freeze drying and is mixed with the TGF-β of the amt. sufficient for the TGF-βto give rise to a substantially irreversible bond to the DMB. When a patient is dosed with this compsn., bone derivation is induced and the hard non-absorbable neobone is formed. The compsn. is preferably formed as a malleable and plastic substrate of a non-liquid type which may be so shaped as to comply with the section where the growth of the bone is desired.  The neobone may be formed in accordance with the form and shape of this substrate.
BACKGROUND: Heart rate variability (HRV) analysis has shown promise as a valuable complementary tool for clinical assessment in trauma cases. This study aims to evaluate the utility of HRV in monitoring different severities of hemorrhagic shock (HS) and its correlation with traditional hemodynamic and metabolic parameters.
METHODS: Male Sprague-Dawley rats were divided into different experimental groups, including those with and without vagotomy, and were exposed to different classes of decompensatory HS. To induce varying severities of HS, volume resuscitation was delayed by gradually returning 0%, 20%, or 50% of the shed blood volume at the end of the compensation phase, referred to as 0% DFR, 20% DFR, and 50% DFR class, respectively. Hemodynamic parameters were monitored, and HRV was calculated. Levels of TNF-α and IL-10 were determined in lung tissue at the end of the experiments. Correlations between HRV, hemodynamic parameters, inflammatory gene expression and arterial blood gas variables were evaluated.
RESULTS: HRV showed increased power of the low-frequency (LF) and respiratory sinus arrhythmia (RSA) in all groups during the hypotension phase of HS (Nadir 1). Subdiaphragmatic vagotomy blunted the increase in the LF component in the Nadir 1. After volume resuscitation, systolic blood pressure (SBP), RSA and LF returned to baseline in the 0% DFR and 20% DFR classes. However, animals in 50% DFR class exhibited a reduced SBP and LF and lower pH. Notably, strong correlations were found between LF and SBP as well as tissue hypoperfusion markers. The expression of TNF-α in the lung was increased in all HS groups, while this gene expression was significantly higher in the vagotomized animals.
CONCLUSION: The alterations in HRV components were found to be significantly correlated with the hemodynamic and metabolic status of the animals, while showing no association with inflammatory responses. Additionally, the intervention of subdiaphragmatic vagotomy significantly impacted both HRV components and inflammatory responses. Collectively, these findings suggest the potential of HRV components for the assessment of the presence and severity of HS.
Two usual care diabetes educators will each identify three primary care practices of mid to large size to include in the control arm and participate in the usual care intervention. Uneven group assignment accounts for the amount of time (one day equivalent/per week) that the intervention diabetes educators will devote to each primary care practice versus the full-time availability of the usual care diabetes educators to see patients at the outpatient, hospital-based program. Like the experimental arm, an estimated 2,200 patients with diabetes will meet eligibility criteria for DSME referral. Patients will not be formally recruited or enrolled into the control arm; data will be extracted from the electronic medical record system to evaluate patient-level outcomes.
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the United States, and morbidity and mortality from COPD continue to rise. Despite the magnitude of the problem, therapeutic options are limited - particularly in comparison to cardiovascular disease. Smoking cessation is essential to the treatment and prevention of COPD. However, although smoking is the principal cause of COPD, only a minority of smokers develops symptomatic COPD and many former smokers develop COPD years to decades after they have stopped smoking. The only other medical intervention proven to reduce mortality from COPD is supplemental oxygen therapy. There is therefore an urgent need for newer understandings of the pathophysiology of COPD that might lead to the development of better therapies for COPD.

MESA-Lung is ancillary of the ongoing Multi-Ethnic Study of Atherosclerosis (MESA). MESA-lung will utilize the various existing measures of endothelial function that have been already been collected in MESA (flow-mediated dilatation \[FMD\] and related biomarkers and gene polymorphisms) to test the hypotheses that the endothelial dysfunction occurs in the clinical COPD.
BiPS Medical has developed a wearable, wireless device that conveniently monitors important vital sign trends over time - blood pressure (diastolic \& systolic), heart and respiration rates, blood oxygen level (SPO2) and body temperature - to aid in identifying clinical deterioration. The device is base on a combination of inflatable mini finger cuff and photoplethysmograph technology.

The aim of this study is to collect data for evaluating and calibrating of the BiPS monitor for monitoring patient vital signs and compare it to current standard of care hospital monitors. The study population includes a total of 50 adult patients that are connected to an arterial line as part of their routine care. The BiPS non-invasive monitor will be attached to participating patients during their stay in the ICU/ recovery in cardiac ICU/Post Anesthesia Care Unit /other hospital designated unit. The device will be placed on the patient for 60 minutes while in hospital bed, in which up to 20 blood pressure measurements are performed (each takes up to 60 seconds). Heart and respiration rates, body temperature and SPO2 will be measured continuously while the device is attached to the patient hand.
The invention relates to a device for producing small particles of a certain substance. The device includes first inlet means (4) for a solution or a suspension containing the substance and second inlet means (3) for an atomizing agent. The device further includes mixing means (12) for the solution and the atomizing agent and outlet means (13) for the particles. First (9, 10) and second (14, 11) conduit means are provided from the first (4) and second (3) inlet means respectively to the mixing means (12). According to the invention the first (9, 10) and second (14, 11) conduit means meet each other at the mixing means (12) at an angle of at least 30o. The invention also relates to a corresponding method and to use of the device and the method as well as to particles obtained by the method.
OBJECTIVES: We aimed to evaluate the ability of the parasternal intercostal (PIC) thickening fraction during spontaneous breathing trial (SBT) to predict the need for reintubation within 48 h after extubation in surgical patients with sepsis.
METHODS: This prospective observational study included adult patients with sepsis who were mechanically ventilated and indicated for SBT. Ultrasound measurements of the PIC thickening fraction and diaphragmatic excursion (DE) were recorded 15 min after the start of the SBT. After extubation, the patients were followed up for 48 h for the need for reintubation. The study outcomes were the ability of the PIC thickening fraction (primary outcome) and DE to predict reintubation within 48 h of extubation using area under receiver characteristic curve (AUC) analysis. The accuracy of the model including the findings of right PIC thickening fraction and right DE was also assessed using the current study cut-off values. Multivariate analysis was performed to identify independent risk factors for reintubation.
RESULTS: We analyzed data from 49 patients who underwent successful SBT, and 10/49 (20%) required reintubation. The AUCs (95% confidence interval [CI]) for the ability of right and left side PIC thickening fraction to predict reintubation were 0.97 (0.88-1.00) and 0.96 (0.86-1.00), respectively; at a cutoff value of 6.5-8.3%, the PIC thickening fraction had a negative predictive value of 100%. The AUCs for the PIC thickening fraction and DE were comparable; and both measures were independent risk factors for reintubation. The AUC (95% CI) of the model including the right PIC thickening fraction > 6.5% and right DE ≤ 18 mm to predict reintubation was 0.99 (0.92-1.00), with a positive predictive value of 100% when both sonographic findings are positive and negative predictive value of 100% when both sonographic findings are negative.
CONCLUSIONS: Among surgical patients with sepsis, PIC thickening fraction evaluated during the SBT is an independent risk factor for reintubation. The PIC thickening fraction has an excellent predictive value for reintubation. A PIC thickening fraction of ≤ 6.5-8.3% can exclude reintubation, with a negative predictive value of 100%. Furthermore, a combination of high PIC and low DE can also indicate a high risk of reintubation. However, larger studies that include different populations are required to replicate our findings and validate the cutoff values.
Chronic pain is characterised by a protective mechanism of the neuro-immune-endocrine systems potentially exacerbated by loading exposures, conditioning, psychological, socio-economic, lifestyle, comorbid mental health and non-modifiables such as genetics, (O'Sullivan et al 2016). Pain education can be a useful basis for helping patients to manage their symptoms and return to good daily function. However a biomedical approach to chronic pain persists in medical communities, whilst persistent pain populations increase and incidences of opioid addiction are growing secondary to poor pain management. Biomedical models of pain are likely to induce fear avoidant behaviour and exacerbate chronicity (Wertli et al 2014). In order to change the prevailing biomedical approach to chronic pain the International Association for the Study of Pain (IASP) have provided detailed pain curricula content for different medical and allied health professional courses. Briggs et al (2015) found that out of 15 'representative European countries' less than a handful of universities from 3 countries had implemented distinctly identifiable pain education teaching. However they may be other forms of pain education that are taking place in pre-registration healthcare professional education. This study aims to establish the levels of chronic pain management knowledge and attitudes prevail in the UK and Ireland amongst pre-registration healthcare professionals.
Randomized controlled split-face study. One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will be prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months. The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
The remediation intervention will consist of a sequence of computerized cognitive exercises designed to improve a variety of aspects of attention, through repeated drill-and-practice (Bell, Bryson, Greig, Corcoran, \& Wexler, 2001; Bracy, 1995; Kurtz et al., 2007). Exercises will be started and continued at the highest level of difficulty, in order to best establish improvement over time. Components of the planned intervention produce performance gains on practiced tasks (e.g., Wexler et al., 1997) and generalization of improvement to other tasks (Kurtz et al., 2007). All training on computer exercises will be conducted with coaching from staff trained in these procedures.
PURPOSE: A nanoparticle is provided to be used as a drug carrier and has a binding force sufficient to have stability in a body. CONSTITUTION: Poly (ethylene glycol) - block - poly (phosphorester) copolymer is represented by Formula 1. In Formula 1, m and n are each independently an integer of 20 to 400. R is an alkyl group, R' is a hydrogen atom or an alkyl group, and the is polyalkyleneglycol, polyvinylpyrrolidone, polyacrylamide, polyglycolide, or a copolymer thereof, or a derivative thereof. The -[A]m- has a number average molecular weight of 500~50,000 Da. Also, the nanoparticle having a core-shell structure includes a copolymer of Formula 1 and an ion bonding material.
Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 milligram (mg) (4\*140 mg capsules) once daily (QD) from Days 1- 4; on Days 5-11 ibrutinib 140 mg capsule QD in combination with erythromycin 500 mg tablet 3 times daily (TID); on Days 12-13 ibrutinib 140 mg capsule QD; on Days 14-18 ibrutinib 560 mg (4\*140 mg capsules) QD; on Days 19-25 ibrutinib 140 mg capsule QD in combination with voriconazole 200 mg tablet twice daily (BD); on Days 26-27 ibrutinib 140 mg capsule orally QD; and on Day 28 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
There is no consensus on the efficacy of perioperative immunonutrition in patients with upper gastrointestinal (GI) cancer surgery. We clarified the impact of perioperative immunonutrition on postoperative outcomes in patients with upper GI cancers. We searched MEDLINE (PubMed), MEDLINE (OVID), EMBASE, Cochrane Central Register of Controlled Trials, Web of Science Core Selection, and Emcare from 1981-2022 using search terms related to immunonutrition and upper GI cancer. We included randomized controlled trials. Intervention was defined as immunonutritional therapy, including arginine, n-3 omega fatty acids, or glutamine during the perioperative period. The control was defined as standard nutritional therapy. The primary outcomes were infectious complications, defined as events with a Clavien-Dindo classification grade ≥ II that occurred within 30 days after surgery. After screening, 23 studies were included in the qualitative synthesis and in the quantitative synthesis. The meta-analysis showed that immunonutrition reduced infectious complications (relative risk ratio: 0.72; 95% confidence interval: 0.57-0.92; certainty of evidence: Moderate) compared with standard nutritional therapy. In conclusion, nutritional intervention with perioperative immunonutrition in patients with upper GI cancers significantly reduced infectious complications. The effect of immunonutrition for upper GI cancers in reducing the risk of infectious complications was about 30%.
Three precut KT I strips with a width of 5 cm were used. The first strip is applied with the subject's wrist in fully extended hand position. Middle and ring fingers through the holes with the base of the tape as anchored to the knuckles, and then the tape was applied with 15%-25% tension covering the palm and the wrist, and the remainder of the tape without any tension from the wrist up to the forearm. The same process is repeated for the second I-strip, which was applied from the dorsum of the hand to wrist while the wrist in a downward flexed position. The final strip was applied to the carpal tunnel region with 25%-35% tension.
This case report highlights the effective use of intermittent hemodialysis (IHD) in warming a 71-year-old female patient with severe hypothermia who presented with a rectal temperature of 25 °C and signs of hemodynamic instability. The patient, found unconscious after prolonged exposure to cold exacerbated by alcohol consumption, initially showed some improvement in core temperature through active external rewarming methods. However, soon, her temperature plateaued at 27 °C. Patient was deemed unsuitable for extracorporeal membrane oxygenation (ECMO) or cardiopulmonary bypass (CPB) due to her age, and urgent IHD was initiated. This approach resulted in a stable increase in core temperature at approximately 2.0 °C/hr, along with normalization of lactic acidosis, creatinine phosphokinase, and correction of electrolyte imbalances, culminating in her full recovery and discharge after seven days in the hospital.After reviewing this case alongside similar ones from before, this case report highlights the efficacy and safety of IHD as an efficient, readily available, and less invasive method for rewarming moderate to severe hypothermic patients who are hemodynamically unstable patients but do not have cardiac arrest or renal dysfunction. IHD is especially useful when less invasive cooling devices (Artic Sun/ CoolGard) are not available or more invasive extracorporeal life support options (ECMO/ CPB) are either not indicated or unavailable. IHD can also help improve concurrent electrolyte imbalances and/or toxin buildup. The report further emphasizes the necessity of monitoring for potential complications, such as post-dialysis hypophosphatemia and rebound hyperkalemia, following successful rewarming.